Publish
Home
Live
new
RH Journal
ResearchCoin
Grants
Funding
Browse
Journals
Hubs
Tools
Lab Notebook
Beta
Reference Manager
Resources
Verify Identity
Community
Support
About
Terms
Privacy
Issues
Docs
Author
Log in
Sign up
MY
Mari Yamamoto
Author with expertise in Prevention and Management of Postoperative Nausea and Vomiting
Achievements
This user has not unlocked any achievements yet.
Key Stats
Upvotes received:
0
Publications:
5
(40% Open Access)
Cited by:
0
h-index:
37
/
i10-index:
90
Reputation
Biology
< 1%
Chemistry
< 1%
Economics
< 1%
Show more
How is this calculated?
Overview
Publications
5
Peer Reviews
Comments
Grants
Publications
0
Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer: a multicenter prospective cohort study in the Setouchi Breast Project-14
Shogo Nakamoto
et al.
Jun 18, 2024
Oncology
Immunology
0
Paper
Oncology
Immunology
0
Save
0
The effect of exercise and educational programs for breast cancer patients on the development of breast cancer-related lymphoedema: secondary endpoint from a randomized controlled trial in the Setouchi Breast Project-10
Shogo Nakamoto
et al.
Jul 9, 2024
Oncology
Internal Medicine
0
Paper
Oncology
Internal Medicine
0
Save
0
Unveiling the Patterns of Water Diuresis in Profound Hyponatremia Management in Intensive Care Unit Settings
Koya Nagase
et al.
Aug 9, 2024
Hyponatremia treatment guidelines recommend avoiding excessive increases in serum sodium concentration (s[Na]) to prevent osmotic demyelination syndrome. Although an unexpected rise in s[Na] has been attributed to water diuresis during the treatment of hyponatremia, clinical courses of water diuresis are unclear. We conducted this study to investigate the clinical characteristics of water diuresis during profound hyponatremia management.
Molecular Biology
Internal Medicine
0
Paper
Molecular Biology
Internal Medicine
0
Save
0
A randomized, double-blind, placebo-controlled phase II study of olanzapine based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)
Hitomi Sakai
et al.
Sep 1, 2024
Nausea and vomiting are common adverse events associated with trastuzumab deruxtecan (T-DXd). We evaluated the efficacy of an olanzapine-based triplet regimen for preventing nausea and vomiting in patients receiving first cycle T-DXd.
Oncology
Internal Medicine
0
Paper
Oncology
Internal Medicine
0
Save
0
1816O A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)
Hitomi Sakai
et al.
Sep 1, 2024
Oncology
Internal Medicine
0
Paper
Oncology
Internal Medicine
0
Save